Baxalta Board Of Directors Declares Inaugural Dividend; Approves $1 Billion Share Repurchase Authorization

DEERFIELD, Ill.--(BUSINESS WIRE)--The Board of Directors of Baxalta Incorporated (NYSE: BXLT) today declared a quarterly cash dividend of $0.07 per share of common stock. The quarterly dividend will be paid on October 1, 2015, to stockholders of record as of the close of business on September 4, 2015.

“Baxalta has a very competitive and compelling financial profile and remains committed to a disciplined capital allocation strategy that balances reinvestment in our business with returning value to shareholders”

Baxalta's Board of Directors has also approved a share repurchase authorization which will allow the company to purchase up to $1 billion of its common stock. Shares can be repurchased in the open market at times and amounts determined by the company based on its evaluation of market conditions and other factors.

“Baxalta has a very competitive and compelling financial profile and remains committed to a disciplined capital allocation strategy that balances reinvestment in our business with returning value to shareholders,” said Robert Hombach, chief financial officer and chief operations officer, Baxalta. “The announcement today reflects our continued confidence in our long-term strategy, our ability to generate significant free cash flow, and drive sustainable and profitable growth while enhancing value for patients, customers and shareholders.”

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International Inc., Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

Forward-Looking Statements

This release includes forward-looking statements concerning Baxalta’s dividend and share repurchase authorization. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continued strength in the company’s financial position, including cash flows; future decisions of the board of directors of the company with respect to the repurchase of shares and the payment of dividends relative to alternative uses of funds; and other risks identified in Baxalta’s registration statement on Form 10 and other Securities and Exchange Commission filings, all of which are available on Baxalta’s website. Baxalta does not undertake to update its forward-looking statements.